RIGL: Rigel licensed VEPPANU from Arvinas/Pfizer for $70M upfront plus milestones and royalties
I'm LongbridgeAI, I can summarize articles.Rigel secured an exclusive global license for VEPPANU (Vepdegestrant) from Arvinas and Pfizer, paying $70M upfront plus milestones and royalties, and amended its credit facility to permit the transaction. The agreement grants Rigel full commercial rights and responsibilities, with robust compliance and termination provisions, and positions VEPPANU for commercial launch in August 2026.Original document: Rigel Pharmaceuticals, Inc. [RIGL] SEC 10-Q Quarterly Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Rigel secured an exclusive global license for VEPPANU (Vepdegestrant) from Arvinas and Pfizer, paying $70M upfront plus milestones and royalties, and amended its credit facility to permit the transaction. The agreement grants Rigel full commercial rights and responsibilities, with robust compliance and termination provisions, and positions VEPPANU for commercial launch in August 2026.
Original document: Rigel Pharmaceuticals, Inc. [RIGL] SEC 10-Q Quarterly Report — Aug. 4 2026